Y90 for Hepatocellular-Cholangiocarcinoma

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma


https://link.springer.com/article/10.1007/s00270-017-1648-7

Results

Ten patients (median age 59 years; six men, four women) with unresectable cHCC-CC underwent 14 RE treatments with resin (n = 6 patients) or glass (n = 4 patients) microspheres. Clinical toxicities were limited to grade 1–2 fatigue, anorexia, nausea, or abdominal pain. No significant biochemical toxicities were observed. Median overall survivals from the first RE treatment and from initial diagnosis were 10.2 and 17.7 months, respectively. Six of seven patients with elevated tumor biomarker levels before RE showed decreased levels after treatment (median decrease of 72%, range 13–80%). Best hepatic radiological response was 60% partial response and 40% stable disease by modified RECIST, and 100% stable disease by RECIST v1.1. Poor performance status and the presence of macrovascular invasion were identified as predictors of reduced survival after RE.
Conclusion

RE appears to be a safe and promising treatment option for patients with unresectable cHCC-CC.
Level of Evidence

Level 4.